Physician profile
Anthony E Zerangue
NPI 1477523538
$20,409.11
in general payments reported to CMS, 2019-2025
55 companies · $4,140 in 2025
The $4,140 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $1,694 · 2021: $2,292 · 2022: $3,313 · 2023: $4,048 · 2024: $3,854 · 2025: $4,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,041.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,383.64 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,997.59 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,599.91 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Glaxosmithkline, LLC. | $1,386.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,178.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $920.28 | 2020-2025 | Rexulti, Vyepti, Abilify Asimtufii |
| Lilly USA, LLC | $876.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $701.08 | 2022-2025 | |
| Almatica Pharma LLC | $698.30 | 2021-2025 | Loreev Xr, Teriparatide |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $552.14 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $533.24 | 2019-2025 | Trintellix |
| Paratek Pharmaceuticals, INC. | $503.34 | 2022-2025 | Nuzyra, Xhance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.81 | 2020-2024 | Tradjenta, Jardiance |
| Amgen INC. | $453.74 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $445.14 | 2020-2025 | Rexulti |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $444.86 | 2020-2025 | |
| Axsome Therapeutics, INC. | $437.81 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Allergan, INC. | $322.43 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $223.78 | 2020-2025 | Austedo Xr, Austedo |
| Abbott Laboratories | $213.34 | 2021-2023 | Confirm Rx, Freestyle Libre |
| Supernus Pharmaceuticals, INC. | $177.74 | 2020-2024 | Qelbree |
| Scilex Pharmaceuticals INC. | $155.44 | 2019-2024 | |
| Radius Health, INC. | $141.13 | 2020-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $119.54 | 2019-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $114.60 | 2024-2025 | Voquezna |
| Jazz Pharmaceuticals INC. | $99.35 | 2020-2021 | |
| Tolmar, INC. | $94.09 | 2023-2025 | Jatenzo |
| Esperion Therapeutics, INC. | $91.23 | 2021-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $88.84 | 2021 | |
| Collegium Pharmaceutical, INC. | $85.16 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $79.23 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $68.90 | 2020-2023 | Linzess |
| Biohaven Pharmaceutical Holding Company Ltd. | $61.31 | 2022 | |
| Mannkind Corporation | $59.40 | 2022 | |
| Astellas Pharma US INC | $59.12 | 2022-2023 | Myrbetriq |
| Corium, LLC | $49.94 | 2023 | Azstarys |
| Indivior INC. | $48.28 | 2019-2024 | Sublocade |
| Shire North American Group INC | $43.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.16 | 2020-2022 | |
| Verona Pharma, INC. | $38.27 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $34.54 | 2024-2025 | Camzyos |
| Orexo US, INC. | $31.88 | 2023 | Zubsolv |
| Sentynl Therapeutics, INC. | $31.61 | 2019 | |
| Exact Sciences Corporation | $30.11 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $28.71 | 2020 | |
| Currax Pharmaceuticals LLC | $26.95 | 2021 | |
| Sumitomo Pharma America, INC. | $23.29 | 2023 | Gemtesa |
| Alkermes, INC. | $19.70 | 2025 | Aristada, Lybalvi |
| Mdd US Operations, LLC | $19.27 | 2019 | |
| Impel Pharmaceuticals INC. | $19.19 | 2023 | Trudhesa |
| Eisai INC. | $17.34 | 2020 | |
| Antares Pharma, INC. | $16.83 | 2023 | Xyosted, Nocdurna, Tlando |
| Idorsia Pharmaceuticals US INC | $14.39 | 2023 | Quviviq |
| Circassia INC. | $13.87 | 2019 | |
| Assertio Therapeutics, INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Zerangue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.